Annals of Neurology · 1986 · 348 citations · 27 references
Life SciencesNeurologyNeuroscienceNeurochemistryNeurodegenerationNeuropharmacologyMolecular Basis Of NeurodegenerationNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersDopaminergic NeurodegenerationIntracellular Inclusion BodiesNeurological PathogenesisParkinson Disease PathologyParkinson's Disease ModelsParkinsonian Degeneration
Systemic administration of the recently discovered neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces severe clinical parkinsonism and degeneration of the substantia nigra in humans and monkeys. In previous studies, no convincing structural damage to nerve cells outside the substantia nigra could be demonstrated in subhuman primates. Using a protracted MPTP regimen and older animals, we now report locus ceruleus lesions and eosinophilic inclusion bodies in squirrel monkeys. The inclusions were seen only in areas where Lewy bodies are found in human Parkinson's disease. No such abnormalities were seen in control animals. These findings suggest that similarities between the neuropathology of MPTP-induced parkinsonism in the monkey and human Parkinson's disease are greater than first thought and increase the usefulness of the MPTP monkey model for research in Parkinson's disease.
27
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
J. William Langston, Philip L. Ballard, James W. Tetrud et al. · Science · 1983 · 4.9K citations
Richard S. Burns, Chuang C. Chiueh, Sanford P. Markey et al. · Proceedings of the National Academy of Sciences · 1983 · 2.1K citations · Full text
Medicine, Neuroscience, Pharmacology +17
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Glenn C. Davis, Adrian Williams, Sanford P. Markey et al. · Psychiatry Research · 1979 · 1.4K citations
Medicine, Neurology, Pharmacology +16